IPCA Laboratories
1,507.80
-20.00(-1.31%)
Market Cap₹38,253.52 Cr
PE Ratio45.42
IndustryHealthcare
Company Performance:
1D-1.31%
1M+2.86%
6M+4.01%
1Y-4.55%
5Y+42.52%
View Company Insightsright
More news about IPCA Laboratories
13Nov 25
IPCA Laboratories Reports Strong Q2 Growth with 25% Rise in Net Profit
IPCA Laboratories Limited announced robust Q2 FY26 financial results. Consolidated net total income increased by 9% to Rs. 2,584.36 crore, while consolidated net profit grew by 23% to Rs. 282.57 crore. The company saw growth in various segments, with Indian formulations income up 8% and exports income rising 7%. The API segment experienced significant 28% growth. IPCA's consolidated EBITDA margin improved to 21.68% from 19.10% in the previous year. Domestic formulations revenue reached Rs. 1,018.90 crore, while API exports surged by 45% to Rs. 320.94 crore.
17Oct 25
IPCA Laboratories to Divest Drug Intermediates and API Manufacturing Unit for ₹22.15 Crore
IPCA Laboratories Ltd has approved the sale of its drug intermediates and API manufacturing unit in Ankleshwar, Gujarat to Suleshvari Pharma Private Limited for ₹22.15 crore. The sale includes leasehold land, factory buildings, plant & machinery, and employees. The unit contributed ₹50.24 crore (0.74% of total income) in FY 2024-25. The transaction, expected to complete by December 31, 2025, aims to optimize manufacturing facilities and reduce operational costs. Suleshvari Pharma, not related to IPCA's promoters, operates in the same sector. The sale is subject to necessary approvals and complies with SEBI regulations.
16Oct 25
Ipca Laboratories Expands European Presence with New German Subsidiary
IPCA Laboratories Limited has incorporated a wholly owned subsidiary, Ipca Pharmaceuticals GmbH, in Germany with an initial paid-up capital of €25,000. The new entity will hold product registrations, participate in institutional business, and distribute generic formulations in Germany. This strategic move aims to expand IPCA's European footprint and strengthen its presence in the German pharmaceutical market.
24Sept 25
Ipca Laboratories Inks Landmark Deal for Monoclonal Antibody Biosimilar Development
IPCA Laboratories signed a Technology Transfer and Joint Development Agreement with BioSimilar Sciences PR LLC (BSS) for a monoclonal antibody biosimilar. The partnership targets a $4 billion U.S. market growing at 12% annually. BSS gains exclusive rights for USA and Canada, with non-exclusive rights in select Latin American countries. IPCA will receive milestone fees and royalties. The first biosimilar launch is targeted for 2027, with new molecules set for FDA approval in 2028/29. The collaboration leverages OcyonBio's 60 million unit sterile filling capacity in Puerto Rico, aiming to strengthen the U.S. supply chain for essential medicines and create biotech jobs.
13Aug 25
IPCA Labs Revises EBITDA Margin Guidance, Outlines Growth Strategy
IPCA Laboratories has revised its financial projections and growth plans. The company lowered its EBITDA margin improvement target to 75 basis points for the current fiscal year. It aims for 9-10% topline growth by FY26. In the US market, IPCA plans to launch 5-6 new products annually and has 15-16 products in development. The company also updated on its Unichem acquisition, stating that the previously projected EBITDA of Rs 300.00 crore is unlikely to be achieved this year, but expects improvement in coming quarters.
11Aug 25
IPCA Laboratories Reports 10% Revenue Growth and 28% Profit Surge in Q1 FY26
IPCA Laboratories Limited announced robust Q1 FY26 financial results. Consolidated net total income increased by 11% to ₹2,341.51 crore, while consolidated net profit grew by 18% to ₹234.42 crore. The company's performance was driven by growth in both domestic and export markets. Indian formulations income rose by 10% to ₹961.01 crore, and export income increased by 18% to ₹699.76 crore. The standalone EBITDA margin improved to 23.82% from 22.25% in the previous year. The formulations business showed strong growth, with domestic formulations up 10% and export formulations up 14%. The API segment also contributed to overall growth, increasing by 7%.
01Jun 25
Ipca Labs Receives 'Add' Rating from Dolat Capital Post Q4 Results
Dolat Capital has maintained an 'Add' rating on Ipca Laboratories Limited following its Q4 results. The brokerage firm highlights multiple growth drivers including cost efficiencies, Unichem portfolio scale-up, and US market expansion plans. Ipca Labs aims to launch 12-13 new products in the US over the next two years, signaling a strong commitment to portfolio diversification and market share growth in this key pharmaceutical market.
29May 25
IPCA Laboratories: Q4 Profit Rises 14%, but Full-Year EBITDA Margin Falls Short of Guidance
IPCA Laboratories reported a 14% YoY increase in Q4 net profit to ₹68.00 crore, with revenue up 11% to ₹2,247.00 crore. Q4 EBITDA grew 33%. However, full-year EBITDA margin at 19.00% missed the company's 23-24% guidance. A final dividend of ₹2.00 per share was announced.
28Mar 25
IPCA Laboratories to Sell Tarapur Facility and Acquire Unichem Ireland in Strategic Moves
IPCA Laboratories is selling its Tarapur manufacturing facility for 36.90 crore rupees to optimize operations and reduce costs. Simultaneously, the company is acquiring Unichem Laboratories' Irish subsidiary for 4 crore rupees to establish a presence in the European market. The Tarapur sale is expected to complete by June 30, 2025, while the Irish acquisition will be renamed Ipca Laboratories (Europe) Ltd. These strategic moves aim to streamline manufacturing and expand international presence.
IPCA Laboratories
1,507.80
-20.00
(-1.31%)
1 Year Returns:-4.55%
Industry Peers
Sun Pharmaceutical
1,728.70
(-0.42%)
Divis Laboratories
6,436.50
(-0.76%)
Torrent Pharmaceuticals
3,940.30
(-0.24%)
Cipla
1,448.30
(-1.15%)
Lupin
2,179.00
(-0.43%)
Dr Reddys Laboratories
1,191.30
(-1.99%)
Mankind Pharma
2,213.90
(-0.47%)
Zydus Life Science
900.70
(+0.63%)
Alkem Laboratories
5,863.50
(-0.06%)
Aurobindo Pharma
1,167.70
(-0.44%)